Protocol Ledger

NCT03921541 · Phase III · COMPLETED

Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency

Interventional Phase III clinical trial protocol NCT03921541 sponsored by Immedica Pharma in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-05-01 Enrollment: 32 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03921541
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)32 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03921541
Protocol FieldVerified Registry Value
NCT IdentifierNCT03921541
Consolidated Lead SponsorImmedica Pharma
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment32 participants (ACTUAL)
Registered Start Date2019-05-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI